Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Medicines · US (FDA)
Antiepileptics

FDA 2001

Hydantoin derivatives

Phenytoin

Approved 31 Jan 2001OralSuspension

The FDA lists this product in 8 strengths and forms.

Official labelAsk Osler about it

On this page

Composition
Strengths and forms
Official product information

The table holds no label text for this product yet, only the facts beside it. The official product information has the full text.

Composition

Active ingredients: PHENYTOIN 125MG/5ML

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

PHENYTOIN 125MG/5ML · SuspensionANDA040342-001 · Discontinued
PHENYTOIN 125MG/5ML · SuspensionThis page
PHENYTOIN 125MG/5ML · SuspensionANDA040420-001 · Discontinued
PHENYTOIN 50MG · Tablet, chewableANDA200691-001 · Prescription
PHENYTOIN 50MG · Tablet, chewableANDA200565-001 · Prescription
PHENYTOIN 50MG · Tablet, chewableANDA040884-001 · Prescription
PHENYTOIN 125MG/5ML · SuspensionANDA089892-001 · Discontinued
PHENYTOIN 125MG/5ML · SuspensionANDA040521-001 · Prescription

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application ANDA040342.

More in antiepileptics

BrivaracetamSolution

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Brand name: Phenytoin
Drug class: Hydantoin derivatives
Group: Antiepileptics
Route: Oral
Dosage form: Suspension
Applicant: Vistapharm LLC
Status: Discontinued
FDA approval: 31 Jan 2001
Application: ANDA040342-002
RxCUI: 8183

Guidelines

Guidelines in neurology608 guidelines in the library

FDA 2025

Subvenitelamotrigine · Suspension

FDA 2025PerampanelSuspension

FDA 2023MethsuximideCapsule

FDA 2022LacosamideSolution

FDA 2021Eprontiatopiramate · Solution

FDA 2021PregabalinTablet, extended release

FDA 2020Sesquientfosphenytoin sodium · Solution

FDA 2019RufinamideSuspension

FDA 2019VigabatrinTablet

FDA 2018OxcarbazepineTablet, extended release

FDA 2018Vigadronevigabatrin · For solution

FDA 2017TopiramateCapsule, extended release

FDA 2013Trokendi XRtopiramate · Capsule, extended release

FDA 2013LamotrigineTablet, orally disintegrating